VANCOUVER, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Thai Freeze Dry Co. Ltd. (“TFD”) are pleased to announce they have entered into a Letter of Intent (“LOI”) to develop and sell a line of products that incorporate both companies’ IP and technology for enhancing palatability and bioavailability of beneficial molecules including, but not limited to, cannabinoids, into NeutriSci’s existing and pipeline product formats.
The pilot formulation development and testing program to be conducted under this LOI shall focus on creation of test formulations of NeutriSci’s patented technology tablets to be modified through incorporation of TFD’s proprietary technology together with cannabinoids and other ingredients under TFD’s umbrella of products. Testing will be conducted at TFD’s facilities in Chiang Mai, Thailand.
For the past 15 years, TFD has been developing a disruptive technology that could have a strong impact on traditional herbal medicine, food, beverage, supplement and cosmetic industries including but not limited to the cannabis industry. Along the way, they have achieved FDA approval for their factory and all of their products, GMP Certification, Halal approval and USA FDA approval as a food factory.
TFD’s Cellular Fraction-Line (CFL) technology delivers products with sustained cellular integrity, high bioactivity as well as high bio-availability. “Potentiated cannabis powder” combines the fresh whole leaf powder derived from TFD’s CFL technology with the highly concentrated extract to bring together the high levels of targeted active compounds with the natural synergy of whole-leaf powder.
In this way, TFD approaches the “holy grail” - cannabis in its natural state - its fresh form - displaying the medicinal bioactivity of the cannabis plant as it grows in nature. Thanks to CFL, customers are getting everything from the whole plant except for water, including compounds that we may not yet have discovered.
NeutriSci’s Cryolisation process is used to prepare oral dosage forms comprising cannabinoid and stilbenoid compounds which improve the dissolution rate and bioavailability of cannabinoid compounds.
Preliminary research data indicate that cannabinoid and stilbenoid formulations prepared using the Cryolisation process increase absorption rates of cannabinoid compounds 4-5 times over consumption of cannabinoid compounds alone. The tested formulations appear to increase the amount of active ingredient the body can absorb while simultaneously increasing the rate of absorption with THC and CBD detected in the bloodstream.
NeutriSci’s Cryolisation technology may provide an opportunity for manufacturers of cannabinoid-infused products to use less active ingredient while still achieving the desired results, thus lowering cost of manufacturing, thereby increasing margins.
Dan Foxman, CEO of Thai Freeze Dry, stated, “The list of formulations using cannabis as the catalyst ingredient in combination with other Thai medicinal herbs has huge potential. Our concept of "potentiated" herbs that combine the unnaturally high levels of active compounds achieved by extraction, with our whole-food herbal powders that contain all the co-factors that allow the active compounds to function optimally with our body's adaptive systems, has the potential to have a strong impact on the entire nutraceutical industry.”
Mr. Foxman continued, “NeutriSci’s technology could be a perfect fit for us to create several new products, not only for the cannabis industry. We are looking forward to advance this collaboration as quickly as possible.”
Glen Rehman, CEO of NeutriSci International said, “Apart from the booming cannabis side of things, Thai Freeze Dry is producing some very interesting herb products, such as black rice powder, which demonstrates appetite satisfying properties. Thai Freeze Dry’s sprouted black rice powder tells your body that you are full and no longer hungry. Combined with our technology, we will explore the opportunity to develop a sublingual black rice powder tablet for the weight loss market which is now worth $72.7 billion(1) in the US alone.”
(1) source: www.webwire.com/ViewPressRel.asp?aId=236237
About Thai Freeze Dry
Thai Freeze Dry (TFD), headquartered in Chiang Mai, produces 35 FDA approved herbal powders and 10 herbal formulations using its proprietary Cellular Fraction-Line Technology with additional products pending approval. This advanced and progressive process allows Thai Freeze Dry to maintain the medicinal bioactivity of a live plant while providing the safety of a stable commodity. It provides highly bioactive, stable, bio-available and concentrated products.
For the past 15 years, TFD has been processing Thai herbs and botanicals of the highest quality under GMP conditions. The most popular product to date is sprouted black rice powder which is rich in antioxidants and a natural detoxifier.
TFD is also in a unique position to create synergistic formulations combining Thailand’s traditional medicinal herbs with cannabis in a variety of formulations, each of which addresses specific conditions. It can produce high-value products from the leaves, roots, seeds, and the water removed from the cannabis plant, all of which are presently under-used or not used at all. TFD owns a minority stake in Thai Cannabis Corp. (www.thaicannabiscorporation.com) and has the first call to all their processing.
For more information, please visit: www.thaifreezedry.com
About NeutriSci International
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
NeutriSci has also developed chewable and sublingual cannabis edibles. nu.thc™ as well as nu.cbd™ are healthy and sugar-free cannabinoid tablets that offer a metered dose of THC/CBD, combined with the increased bioavailability and powerful antioxidant properties of pterostilbene, the best out of blueberries. nu.thc™ & nu.cbd™ tablets will be initially sold in California, USA, in collaboration with Nutritional High International Inc.
For more information, please visit: www.neutrisci.com.
Contacts:
Glen Rehman
CEO of NeutriSci International Inc.
Tel: (403) 264-6320
Email: info@neutrisci.com
Dan Foxman
CEO of Thai Freeze Dry Co. Ltd.
Phone: (66) 081 764 4324
Email: daniel.f@thaifreezedry.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
